Journal of NeuroVirology

, Volume 12, Issue 5, pp 403–406

Valproic acid does not affect markers of human immunodeficiency virus disease progression

Authors

    • Department of NeurosciencesUniversity of California
    • HIV Neurobehavioral Research Center
  • Scott Letendre
    • Department of MedicineUniversity of California
  • Maria Buzzell
    • Department of NeurosciencesUniversity of California
  • Jennifer Marquie-Beck
    • Department of NeurosciencesUniversity of California
  • Deborah Lazaretto
    • Department of NeurosciencesUniversity of California
  • Thomas D. Marcotte
    • Department of PsychiatryUniversity of California
  • Igor Grant
    • Department of PsychiatryUniversity of California
  • Ronald J. Ellis
    • Department of NeurosciencesUniversity of California
  • HNRC Group
Short Communication

DOI: 10.1080/13550280600981695

Cite this article as:
Ances, B.M., Letendre, S., Buzzell, M. et al. Journal of NeuroVirology (2006) 12: 403. doi:10.1080/13550280600981695

Abstract

Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

Keywords

CD4+ cellHIVlatent virusvalproic acidviral load

Copyright information

© Journal of NeuroVirology, Inc. 2006